Clinical Trial Update: A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update notes that HS-10566 is being studied in high-risk non-muscle-invasive bladder cancer in Phase 1 and Phase 2. The study is not yet recruiti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• HS-10566

Snippet

Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. | Conditions: High-risk Non-muscle-invasive Bladder Cancer | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING